Supernus Pharmaceuticals (SUPN) Misses Q4 Earnings Expectations

Supernus Pharmaceuticals (NASDAQ:SUPN) reported quarterly earnings results on February 24, 2026 that fell short of analyst expectations.

The Healthcare company reported earnings per share of $-0.07, missing the consensus estimate of $0.22 by $0.29 per share. Revenue came in at $211.6M, beating the estimate of $195.8M.

Supernus Pharmaceuticals's stock moved following the earnings release. The stock currently trades at $56.39 with a market capitalization of $2.6B.